Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.
about
Human recombinant activated protein C for severe sepsisHuman recombinant protein C for severe sepsis and septic shock in adult and paediatric patientsHuman recombinant activated protein C for severe sepsisYear in review in Intensive Care Medicine 2009: I. Pneumonia and infections, sepsis, outcome, acute renal failure and acid base, nutrition and glycaemic control.Activated protein C action in inflammationManaging septic shockAn updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock.The efficacy of activated protein C for the treatment of sepsis: incorporating observational evidence with a Bayesian approachVasopressor requirement during targeted temperature management for out-of-hospital cardiac arrest caused by acute myocardial infarction without cardiogenic shock.Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.Case report: perioperative use of protein c concentrate for protein C deficiency in THA.Protein C and acute inflammation: a clinical and biological perspective.Control groups in recent septic shock trials: a systematic review.Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?An update on activated protein C (xigris) in the management of sepsis.
P2860
Q24201123-BE087E51-608D-4499-9CB4-0E8197519DB9Q24202128-9E50ADD7-730E-4DF3-81AD-695FDB8EE0D0Q24235181-7E417530-0D4C-4222-9F6A-DCF52B2DA2A0Q33631387-3DE108EA-E0F4-4CC0-B31B-45E2489375B2Q33846825-4918E87E-11E9-4EB2-B46B-8B5D29E9341CQ34175564-1372D365-F831-4556-B034-7605D91D37B2Q34486385-F6DFB87D-2744-49E5-AE86-9C8352462BF7Q34981434-4961C608-5257-462F-9DD4-375FF7161BF8Q37313030-63457EBD-D396-4F0B-97EC-C1341329B5A7Q37354434-88EDCFB4-7FF0-4B1F-BA83-685F89CC61B1Q37655314-76837DE0-0027-464C-9751-639719F8E2D9Q38126264-36C1F1BC-78E5-4D43-916F-63925AF3ED68Q38838734-A1D57BDB-E356-4E01-A57E-095204156408Q39370623-EC33D82D-2945-4994-8811-F685791C430DQ42067556-AF0FCA64-1D3B-49A5-AFE5-5F8C0100C78B
P2860
Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.
@en
type
label
Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.
@en
prefLabel
Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.
@en
P2093
P1476
Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.
@en
P2093
Arnaud Desachy
Cornelia Maier
Jean Reignier
Jean-Francois Dhainaut
Jonathan Janes
Julien Charpentier
Mariano A Mignini
Mark Belger
Massimo Antonelli
Michael Cobas-Meyer
P2888
P304
P356
10.1007/S00134-009-1436-1
P577
2009-03-05T00:00:00Z